389 related articles for article (PubMed ID: 27018242)
81. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
[TBL] [Abstract][Full Text] [Related]
82. Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma.
Ribi K; Rondeau S; Hitz F; Mey U; Enoiu M; Pabst T; Stathis A; Fischer N; Clough-Gorr KM
Support Care Cancer; 2017 Sep; 25(9):2833-2842. PubMed ID: 28405846
[TBL] [Abstract][Full Text] [Related]
83. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
84. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.
Fowler N; Kahl BS; Lee P; Matous JV; Cashen AF; Jacobs SA; Letzer J; Amin B; Williams ME; Smith S; Saleh A; Rosen P; Shi H; Parasuraman S; Cheson BD
J Clin Oncol; 2011 Sep; 29(25):3389-95. PubMed ID: 21810687
[TBL] [Abstract][Full Text] [Related]
85. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
[TBL] [Abstract][Full Text] [Related]
86. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Tuscano JM; Dutia M; Chee K; Brunson A; Reed-Pease C; Abedi M; Welborn J; O'Donnell RT
Br J Haematol; 2014 May; 165(3):375-81. PubMed ID: 24606326
[TBL] [Abstract][Full Text] [Related]
87. Absolute lymphocyte count predicts response to rituximab-containing salvage treatment for relapsed/refractory B-cell non-Hodgkin's lymphoma with prior rituximab exposure.
Hung MH; Yu YB; Hsiao LT; Hong YC; Liu JH; Gau JP; Chiou TJ; Chen PM; Tzeng CH; Liu CY
J Chin Med Assoc; 2013 Apr; 76(4):195-200. PubMed ID: 23557886
[TBL] [Abstract][Full Text] [Related]
88. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
89. Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma.
Murayama K; Kiguchi T; Izutsu K; Kameoka Y; Hidaka M; Kato H; Rai S; Kuroda J; Ishizawa K; Ichikawa S; Ando K; Ogura M; Fukushima K; Terui Y
Ann Hematol; 2022 May; 101(5):979-989. PubMed ID: 35244756
[TBL] [Abstract][Full Text] [Related]
90. A Phase III open-label randomized study to compare the efficacy of lenalidomide-rituximab with bendamustine-rituximab in treatment-naïve follicular lymphoma.
Paikaray SK; Gogia A; Kumar L; Sharma A; Biswas AA; Vishnubhatla S; Mallick S
Indian J Cancer; 2023 Oct; 60(4):501-504. PubMed ID: 38185869
[TBL] [Abstract][Full Text] [Related]
91. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.
Gressin R; Daguindau N; Tempescul A; Moreau A; Carras S; Tchernonog E; Schmitt A; Houot R; Dartigeas C; Pignon JM; Corm S; Banos A; Mounier C; Dupuis J; Macro M; Fleury J; Jardin F; Sarkozy C; Damaj G; Feugier P; Fornecker LM; Chabrot C; Dorvaux V; Bouadallah K; Amorin S; Garidi R; Voillat L; Joly B; Celigny PS; Morineau N; Moles MP; Zerazhi H; Fontan J; Arkam Y; Alexis M; Delwail V; Vilque JP; Ysebaert L; Le Gouill S; Callanan MB;
Haematologica; 2019 Jan; 104(1):138-146. PubMed ID: 30171024
[TBL] [Abstract][Full Text] [Related]
92. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.
Luminari S; Goldaniga M; Cesaretti M; Orsucci L; Tucci A; Pulsoni A; Salvi F; Arcaini L; Carella AM; Tedeschi A; Pinto A; Stelitano C; Baldini L
Leuk Lymphoma; 2016; 57(4):880-7. PubMed ID: 26379040
[TBL] [Abstract][Full Text] [Related]
93. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
[No Abstract] [Full Text] [Related]
94. Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
Ribes D; Hachem HEL; Oberic L; Vergez F; Delas A; Belliere J; Protin C; Kamar N; Ferrandiz I; Tavitian S; Laurent C; Huart A; Chauveau D; Ysebaert L; Faguer S
Am J Hematol; 2018 Mar; 93(3):356-362. PubMed ID: 29168251
[TBL] [Abstract][Full Text] [Related]
95. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
[No Abstract] [Full Text] [Related]
96. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.
Ruan J; Shah B; Martin P; Schuster SJ
Ann Oncol; 2016 Jul; 27(7):1226-34. PubMed ID: 27052651
[TBL] [Abstract][Full Text] [Related]
97. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma.
Uchida M; Mori Y; Akiba K; Miyasaka M; Hirano T; Ikesue H; Yamaguchi Y; Takano A; Maegawa N; Shimomura Y; Hosohata K; Muroi N; Ishikawa T; Hashida T; Nakamura T
Biol Pharm Bull; 2020 Oct; 43(10):1577-1582. PubMed ID: 32801282
[TBL] [Abstract][Full Text] [Related]
98. Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
Cencini E; Sicuranza A; Fabbri A; Ferrigno I; Rigacci L; Cox MC; Raspadori D; Bocchia M
Br J Haematol; 2019 Jan; 184(2):223-231. PubMed ID: 30203425
[TBL] [Abstract][Full Text] [Related]
99. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.
Ujjani CS; Jung SH; Pitcher B; Martin P; Park SI; Blum KA; Smith SM; Czuczman M; Davids MS; Levine E; Lewis LD; Smith SE; Bartlett NL; Leonard JP; Cheson BD
Blood; 2016 Nov; 128(21):2510-2516. PubMed ID: 27697771
[TBL] [Abstract][Full Text] [Related]
100. Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma.
Fu S; Wang M; Zhao H; Li R; Lairson DR; Giordano SH; Zhao B; Du XL
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):e616-e623. PubMed ID: 31563564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
